FindTrial
Sign In

UC-MSC

BIOLOGICAL5 trials

Sponsors

Shandong Qilu Stem Cells Engineering Co., Ltd., Shanghai Life Science & Technology, Peking University People's Hospital, Tongji Hospital, PT. Prodia Stem Cell Indonesia

Conditions

Acute Myocardial InfarctionAcute Respiratory Distress SyndromeChronic Kidney DiseasesDecompensated Liver CirrhosisGraft Vs Host DiseaseLeft Ventricular Dysfunction

Phase 1

UC-MSC Transplantation for Left Ventricular Dysfunction After AMI
WithdrawnNCT03902067
Shanghai Life Science & TechnologyAcute Myocardial Infarction, Left Ventricular Dysfunction
Start: 2024-12-01End: 2025-12-31Updated: 2026-05-11
Human Umbilical Cord Mesenchymal Stem Cell(UC-MSC)Delayed Renal Chronic Kidney Disease(CKD3、4 )
NCT05512988
Tongji HospitalChronic Kidney Diseases
Start: 2021-04-13End: 2024-05-31Target: 44Updated: 2022-08-23
Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis
RecruitingNCT07439848
PT. Prodia Stem Cell IndonesiaAcute Respiratory Distress Syndrome
Start: 2023-12-25End: 2026-12-01Target: 15Updated: 2026-02-27

Phase 2

Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis
NCT03529136
Shandong Qilu Stem Cells Engineering Co., Ltd.Decompensated Liver Cirrhosis
Start: 2018-06-01End: 2020-04-30Target: 252Updated: 2018-05-18

Phase 3

Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT
CompletedNCT04738981
Peking University People's HospitalGraft Vs Host Disease
Start: 2021-02-01End: 2023-05-02Updated: 2023-06-01

Related Papers

Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
2024-02-2720 citations